Has Ravi Dhawale, MD received payments from drug or device companies?

Yes. Drug and device makers reported $175,232 in general payments to Ravi Dhawale, MD across 854 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ravi Dhawale, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ravi Dhawale, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ravi Dhawale, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1023051299

Payments from drug & device makers

$175,232in general payments, 2019–2025

Across 854 payments — averaging $205.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$116K
Amgen$47K
Dexcom, Inc.$2K
Xeris Pharmaceuticals, Inc.$1K
Novo Nordisk$1K
Insulet Corporation$765
plus $7K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	151	$116,327
Amgen	117	$46,938
Dexcom, Inc.	76	$2,361
Xeris Pharmaceuticals, Inc.	46	$1,108
Novo Nordisk	67	$1,086
Insulet Corporation	36	$765
Lilly USA, LLC	33	$584
Sanofi-aventis U.S. LLC	31	$494
Abbott	24	$437
Corcept Therapeutics	17	$329
Boehringer Ingelheim	20	$326
Bayer	16	$299
BETA Bionics, Inc.	13	$286
Antares Pharma, Inc.	16	$273
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	14	$233
Novartis	12	$231
Neurocrine Biosciences, Inc.	8	$217
Amneal Pharmaceuticals LLC	11	$213
Pfizer	11	$191
Medtronic(2 entities)	7	$186
Almatica Pharma LLC	7	$186
AbbVie	11	$163
Lifescan, Inc.	9	$154
Amarin Pharma, Inc.	8	$143
Cequr Corporation	4	$141
Johnson & Johnson	7	$116
IBSA Pharma Inc.	7	$108
Ipsen Biopharmaceuticals, Inc	2	$100
Radius Health, Inc.	5	$92
Tandem Diabetes Care, Inc.	7	$88
Recordati_rare_diseases_inc.	5	$84
Regeneron Healthcare Solutions, Inc.	4	$70
Merck	5	$69
Kyowa Kirin, Inc.	3	$65
Sequel Med Tech, LLC	3	$59
Kowa Pharmaceuticals America, Inc.	4	$56
EUSA Pharma (US) LLC	3	$50
Endo USA, Inc.	2	$49
Endo Pharmaceuticals Inc.	3	$49
Amryt Pharma Holdings Ltd	3	$48
Ultragenyx Pharmaceutical Inc.	2	$46
Mannkind Corporation	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	2	$37
Halozyme Inc	2	$36
Avvisto Therapeutics, LLC	2	$30
Tolmar, Inc.	2	$29
Shire North American Group Inc	2	$28
BD	1	$26
Soleno Therapeutics, Inc.	1	$24
Ascendis Pharma Endocrinology Inc	1	$20
Valeritas, Inc.	1	$19
Acella Pharmaceuticals, LLC	1	$18
Roche Diabetes Care, Inc.	1	$17
Esperion Therapeutics, Inc.	1	$17
RGH Enterprises LLC	1	$16
Averitas Pharma Inc.	1	$16
Zealand Pharma US, Inc.	1	$13
Currax Pharmaceuticals LLC	1	$12
Clarus Therapeutics Inc.	1	$6

How this compares

$175,232 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio →

Medicare billing

Part B allowed, 2024

$122,369

Medicare patients

591

Services billed

3,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Columbus

Elena ChristofidesColumbus$3.5M
Steven IngColumbus$1.9M
Kathleen DunganColumbus$1.4M
Kyaw SoeColumbus$1.3M
Samuel AndersonColumbus$556K
Kathleen WyneColumbus$510K
Luma GhalibColumbus$180K
Lawrence KirschnerColumbus$142K
Laura RyanColumbus$126K
Jennifer SiposColumbus$75K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →